Related Publications

View by category(s)

 

Search Publications


Prognostic value of deep sequencing method for minimal residual disease detection in multiple

Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R.
Blood   /  May 15, 2014

Association of response endpoints with survival outcomes in multiple myeloma

Lonial S, Anderson KC
Leukemia   /  Feb 28, 2014

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib

George Mulligan, David I. Lichter, Alessandra Di Bacco, Stephen J. Blakemore, Allison Berger, Erik Koenig, Hugues Bernard, William Trepicchio, Bin Li, Rachel Neuwirth, Nibedita Chattopadhyay, Joseph B. Bolen, Andrew J. Dorner, Helgi van de Velde, Deborah Ricci, Sundar Jagannath, James R. Berenson, Paul G. Richardson, Edward A. Stadtmauer, Robert Z. Orlowski, Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Jesús F. San Miguel, Dixie-Lee Esseltine, and Matthew Schu
Blood   /  Jan 30, 2014

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF.
Leukemia. 2014 Mar;28(3):525-42. doi: 1   /  Mar 13, 2014

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.
Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.   /  Mar 13, 2014

DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.

Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J.
Cancer Res. 2010 Sep 1;70(17):6934-44. doi: 10.1158/0008-5472.CAN-10-0282.   /  Sep 1, 2010

DNA methylation in multiple myeloma is weakly associated with gene transcription.

Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J, Salhia B.
PLoS One. 2012;7(12):e52626. doi: 10.1371/journal.pone.0052626   /  Dec 20, 2012

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr, Petar Stojanov, Scott L. Carter, Peter Cruz-Gordillo, Michael S. Lawrence, Daniel Auclair, Carrie Sougnez, Birgit Knoechel, Joshua Gould, Gordon Saksena, Kristian Cibulskis, Aaron McKenna, Michael A. Chapman, Ravid Straussman, Joan Levy, Louise M. Perkins, Jonathan J. Keats, Steven E. Schumacher, Mara Rosenberg, The Multiple Myeloma Research Consortium, Gad Getz, and Todd R. Golub
Cancer Cell   /  Jan 13, 2014

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, San Miguel J, Sonneveld P, Usmani S, Durie BG, Avet-Loiseau H.
Leukemia   /  Aug 26, 2013

The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma.

Hébraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lodé L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H.
Clin Cancer Res.   /  Sep 1, 2013

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.

Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H.
Leukemia   /  Jul 29, 2013

Targeting BRAF in Multiple Myeloma.

O'Donnell E, Raje NS.
Cancer Discovery   /  Aug 3, 2013

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.

Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.
Nature Genetics   /  Aug 18, 2013

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma

Brian A. Walker, Christopher P. Wardell, Lorenzo Melchor, Sanna Hulkki, Nicola E. Potter, David C. Johnson, Kerry Fenwick, Iwanka Kozarewa, David Gonzalez, Christopher J. Lord, Alan Ashworth, Faith E. Davies1, and Gareth J. Morgan
Blood   /  Aug 2, 2012

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ.
Leukemia   /  Jul 2, 2013

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules

E Leich, S Wei�bach, H-U Klein, T Grieb1, J Pischimarov, T Stühmer, M Chatterjee, T Steinbrunn, C Langer, M Eilers, S Knop, H Einsele, R Bargou and A Rosenwald
Blood Cancer Journal   /  Feb 8, 2013

Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.

Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ.
Oncogene   /  Mar 17, 2011

DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription

Sungwon Jung, Seungchan Kim, Molly Gale, Irene Cherni, Rafael Fonseca, John Carpten, Bodour Salhia
PLOS One   /  Dec 20, 2012

DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors

Bodour Salhia, Angela Baker, Gregory Ahmann, Daniel Auclair, Rafael Fonseca, and John Carpten
Cancer Research   /  Sep 1, 2010

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Laura A. Bruins, Jessica E. Schmidt, Scott Van Wier, Xiu-Bao Chang, Chad C. Bjorklund, Rafael Fonseca, P. Leif Bergsagel, Robert Z. Orlowski, and A. Keith Stewart
Blood   /  Aug 2, 2011

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Jake E. Delmore, Ghayas C. Issa, Madeleine E. Lemieux, Peter B. Rahl, Junwei Shi, Hannah M. Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M. Paranal, Jun Qi, Marta Chesi, Anna Schinzel, Michael R. McKeown, Timothy P. Heffernan, Christopher R. Vakoc, P. Leif Bergsagel, Irene M. Ghobrial, Paul G. Richardson, Richard A. Young, William C. Hahn, Kenneth C. Anderson, Andrew L. Kung, James E. Bradner, and Constantine S. Mitsiades
Cell   /  Sep 16, 2011

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, Dispenzieri A, Van Wier SA, Ahmann G, Levy J, Perkins L, Kim S, Henderson K, Vesole D, Rajkumar SV, Jelinek DF, Carpten J, Fonseca R.
Blood   /  Apr 18, 2013

Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten J, Fonseca R.
Haematologica   /  May 28, 2013

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

Weinhold N, Johnson DC, Chubb D, Chen B, F�?�¶rsti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, N�?�¶then MM, M�?�¼hleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K.
Nature Genetics   /  Mar 17, 2013

Targeting the BRAF V600E Mutation in Multiple Myeloma

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS.
Cancer Discovery   /  Jul 22, 2013

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

Jan B. Egan, Chang-Xin Shi, Waibhav Tembe, Alexis Christoforides, Ahmet Kurdoglu, Shripad Sinari, Sumit Middha, Yan Asmann, Jessica Schmidt, Esteban Braggio, Jonathan J. Keats, Rafae Fonseca1, P. Leif Bergsagel, David W. Craig, John D. Carpten, and A. Keith Stewart
Blood   /  Apr 23, 2012

Latest advances and current challenges in the treatment of multiple myeloma.

Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K.
Nat Rev Clin Oncol.   /  Feb 21, 2012

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL.
Blood   /  Mar 26, 2012

Prediction of cytogenetic abnormalities with gene expression profiles.

Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR, Cartron-Mizeracki MA, Qu P, Keller J, Epstein J, Barlogie B, Shaughnessy JD Jr.
Blood   /  Apr 10, 2012

Clonal competition with alternating dominance in multiple myeloma.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL.
Blood   /  Apr 12, 2012

The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.

Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S, Neri A.
Clin Cancer Res.   /  Dec 1, 2011

Multiple myeloma

Palumbo A, Anderson K.
N Engl J Med.   /  Mar 17, 2011

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ.
Blood   /  Oct 13, 2010

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.

Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z.
Nature   /  Feb 3, 2011

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk.

Broderick P, Chubb D, Johnson DC, Weinhold N, F�¶rsti A, Lloyd A, Olver B, Ma YP, Dobbins SE, Walker BA, Davies FE, Gregory WA, Child JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, M�¼hleisen TW, N�¶then MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS.
Nat Genet.   /  Nov 27, 2011

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.
Clin Cancer Res.   /  Oct 12, 2011

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H; International Myeloma Workshop Consensus Panel 2.
Blood   /  Feb 3, 2011

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ.
Blood   /  Jul 8, 2010

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM.
Cancer Cell   /  Oct 19, 2010

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL.
Cancer Cell   /  Feb 1, 2008

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.

Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM.
Proc Natl Acad Sci U S A.   /  Aug 26, 2008

Initial genome sequencing and analysis of multiple myeloma

Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats, Kristian Cibulskis, Carrie Sougnez, Anna C. Schinzel, Christina L. Harview, Jean-Philippe Brunet, Gregory J. Ahmann, Mazhar Adli, Kenneth C. Anderson, Kristin G. Ardlie, Daniel Auclair, Angela Baker, P. Leif Bergsagel, Bradley E. Bernstein, Yotam Drier, Rafael Fonseca, Stacey B. Gabriel, Craig C. Hofmeister, Sundar Jagannath, Andrzej J. Jakubowiak, Amrita Krishnan, Joan Levy, Ted Liefeld, Sagar Lonial, Scott Mahan, Bunmi Mfuko, Stefano Monti, Louise M. Perkins, Robb Onofrio, Trevor J. Pugh, S. Vincent Rajkumar, Alex H. Ramos, David S. Siegel, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Douglas Voet, Wendy Winckler, Todd Zimmerman, John Carpten, Jeff Trent, William C. Hahn, Levi A. Garraway, Matthew Meyerson, Eric S. Lander, Gad Getz, Todd R. Golub
Nature   /  Mar 24, 2011

Polycomb Target Genes Are Silenced in Multiple Myeloma

Antonia Kalushkova, Mårten Fryknäs, Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Maria Eriksson, Sarah Deleu, Peter Atadja, Anders �sterborg, Kenneth Nilsson, Karin Vanderkerken, Fredrik �berg, Helena Jernberg-Wiklund
PLoS one   /  Jul 9, 2010

Gene expression profiling of plasma cells at myeloma relapse from total therapy 2 predicts subsequent survival.

Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B.
Blood   /  Apr 23, 2009

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J
Nature Genetics   /  Mar 26, 2009

A monoclonal gammopathy precedes multiple myeloma in most patients.

Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM.
Blood   /  Feb 20, 2009

Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden

Landgren, O.; Kristinsson, S. Y.; Goldin, L. R.; Caporaso, N. E.; Blimark, C.; Mellqvist, U. H.; Wahlin, A.; Bjorkholm, M.; Turesson, I.
Blood   /  Jan 30, 2009

Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance

Vachon, C. M.; Kyle, R. A.; Therneau, T. M.; Foreman, B. J.; Larson, D. R.; Colby, C. L.; Phelps, T. K.; Dispenzieri, A.; Kumar, S. K.; Katzmann, J. A.; Rajkumar, S. V.
Blood   /  Jan 29, 2009

Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma: a prospective study

Landgren, O.; Kyle, R. A.; Pfeiffer, R. M.; Katzmann, J. A.; Caporaso, N. E.; Hayes, R. B.; Dispenzieri, A.; Kumar, S.; Clark, R. J.; Baris, D.; Hoover, R.; Rajkumar, S. V.
Blood   /  Jan 29, 2009

Characterization of MYC Translocations in Multiple Myeloma Cell Lines

Amel Dib, Ana Gabrea, Oleg K. Glebov, P. Leif Bergsagel, W. Michael Kuehl
JNCI Monographs 2008 2008(39):25-31; doi:10.1093/jncimonographs/lgn011   /  Dec 1, 2008

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J.
Cancer Cell, 12(3):201-14.   /  Sep 10, 2007

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma

Keats, J. J. Fonseca, R. Chesi, M. Schop, R. Baker, A. Chng, W. J. Van Wier, S. Tiedemann, R. Shi, C. X. Sebag, M. Braggio, E. Henry, T. Zhu, Y. X. Fogle, H. Price-Troska, T. Ahmann, G. Mancini, C. Brents, L. A. Kumar, S. Greipp, P. Di
Cancer Cell   /  Aug 14, 2007

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

Annunziata, C. M. Davis, R. E. Demchenko, Y. Bellamy, W. Gabrea, A. Zhan, F. Lenz, G. Hanamura, I. Wright, G. Xiao, W. Dave, S. Hurt, E. M. Tan, B. Zhao, H. Stephens, O. Santra, M. Williams, D. R. Dang, L. Barlogie, B. Shaughnessy, J. D
Cancer Cell   /  Aug 14, 2007

The molecular classification of multiple myeloma

Zhan, F. Huang, Y. Colla, S. Stewart, J. P. Hanamura, I. Gupta, S. Epstein, J. Yaccoby, S. Sawyer, J. Burington, B. Anaissie, E. Hollmig, K. Pineda-Roman, M. Tricot, G. van Rhee, F. Walker, R. Zangari, M. Crowley, J. Barlogie, B. Shaugh
Blood 2006 Sep 15;108(6):2020-8   /  Sep 15, 2006

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

Zhan, F. Hardin, J. Kordsmeier, B. Bumm, K. Zheng, M. Tian, E. Sanderson, R. Yang, Y. Wilson, C. Zangari, M. Anaissie, E. Morris, C. Muwalla, F. van Rhee, F. Fassas, A. Crowley, J. Tricot, G. Barlogie, B. Shaughnessy, J., Jr.
Blood 2002 Mar 1;99(5):1745-57   /  Mar 1, 2002

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

Smadja, N. V. Fruchart, C. Isnard, F. Louvet, C. Dutel, J. L. Cheron, N. Grange, M. J. Monconduit, M. Bastard, C.
Leukemia 1998 Jun;12(6):960-9   /  Jun 1, 1998

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma

Shaughnessy, J., Jr. Gabrea, A. Qi, Y. Brents, L. Zhan, F. Tian, E. Sawyer, J. Barlogie, B. Bergsagel, P. L. Kuehl, M.
Blood 2001 Jul 1;98(1):217-23   /  Jul 1, 2001

Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping

Sawyer, J. R. Lukacs, J. L. Munshi, N. Desikan, K. R. Singhal, S. Mehta, J. Siegel, D. Shaughnessy, J. Barlogie, B.
Blood 1998 Dec 1;92(11):4269-78   /  Dec 1, 1998

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Mulligan, G. Mitsiades, C. Bryant, B. Zhan, F. Chng, W. J. Roels, S. Koenig, E. Fergus, A. Huang, Y. Richardson, P. Trepicchio, W. L. Broyl, A. Sonneveld, P. Shaughnessy, J. D., Jr. Leif Bergsagel, P. Schenkein, D. Esseltine, D. L. Boral,
Blood 2007 Apr 15;109(8):3177-88   /  Apr 15, 2007

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

Hurt, E. M. Wiestner, A. Rosenwald, A. Shaffer, A. L. Campo, E. Grogan, T. Bergsagel, P. L. Kuehl, W. M. Staudt, L. M.
Cancer Cell 2004 Feb;5(2):191-9   /  Feb 1, 2004

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

Hideshima, T. Anderson, K. C.
Nat Rev Cancer 2002 Dec;2(12):927-37   /  Dec 1, 2002

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell

Gabrea, A. Bergsagel, P. L. Chesi, M. Shou, Y. Kuehl, W. M.
Mol Cell 1999 Jan;3(1):119-23   /  Jan 1, 1999

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

Fonseca, R. Debes-Marun, C. S. Picken, E. B. Dewald, G. W. Bryant, S. C. Winkler, J. M. Blood, E. Oken, M. M. Santana-Davila, R. Gonzalez-Paz, N. Kyle, R. A. Gertz, M. A. Dispenzieri, A. Lacy, M. Q. Greipp, P. R.
Blood 2003 Oct 1;102(7):2562-7   /  Oct 1, 2003

Genetics and cytogenetics of multiple myeloma: a workshop report

Fonseca, R. Barlogie, B. Bataille, R. Bastard, C. Bergsagel, P. L. Chesi, M. Davies, F. E. Drach, J. Greipp, P. R. Kirsch, I. R. Kuehl, W. M. Hernandez, J. M. Minvielle, S. Pilarski, L. M. Shaughnessy, J. D., Jr. Stewart, A. K. Avet-Loisea
Cancer Res 2004 Feb 15;64(4):1546-58   /  Feb 15, 2004

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

Debes-Marun, C. S. Dewald, G. W. Bryant, S. Picken, E. Santana-Davila, R. Gonzalez-Paz, N. Winkler, J. M. Kyle, R. A. Gertz, M. A. Witzig, T. E. Dispenzieri, A. Lacy, M. Q. Rajkumar, S. V. Lust, J. A. Greipp, P. R. Fonseca, R.
Leukemia 2003 Feb;17(2):427-36   /  Feb 1, 2003

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

Davies, F. E. Dring, A. M. Li, C. Rawstron, A. C. Shammas, M. A. O'Connor, S. M. Fenton, J. A. Hideshima, T. Chauhan, D. Tai, I. T. Robinson, E. Auclair, D. Rees, K. Gonzalez, D. Ashcroft, A. J. Dasgupta, R. Mitsiades, C. Mitsiades, N. C
Blood 2003 Dec 15;102(13):4504-11   /  Dec 15, 2003

Ploidy status rarely changes in myeloma patients at disease progression

Chng, W. J. Winkler, J. M. Greipp, P. R. Jalal, S. M. Bergsagel, P. L. Chesi, M. Trendle, M. C. Ahmann, G. J. Henderson, K. Blood, E. Oken, M. M. Hulbert, A. Van Wier, S. A. Santana-Davila, R. Kyle, R. A. Gertz, M. A. Lacy, M. Q. Dispenzi
Leuk Res 2006 Mar;30(3):266-71   /  Mar 1, 2006

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS

Chng, W. J. Van Wier, S. A. Ahmann, G. J. Winkler, J. M. Jalal, S. M. Bergsagel, P. L. Chesi, M. Trendle, M. C. Oken, M. M. Blood, E. Henderson, K. Santana-Davila, R. Kyle, R. A. Gertz, M. A. Lacy, M. Q. Dispenzieri, A. Greipp, P. R. Fons
Blood 2005 Sep 15;106(6):2156-61   /  Sep 15, 2005

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Chng, W. J. Santana-Davila, R. Van Wier, S. A. Ahmann, G. J. Jalal, S. M. Bergsagel, P. L. Chesi, M. Trendle, M. C. Jacobus, S. Blood, E. Oken, M. M. Henderson, K. Kyle, R. A. Gertz, M. A. Lacy, M. Q. Dispenzieri, A. Greipp, P. R. Fonseca
Leukemia 2006 May;20(5):807-13   /  May 1, 2006

Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling

Chng, W. J. Kumar, S. Vanwier, S. Ahmann, G. Price-Troska, T. Henderson, K. Chung, T. H. Kim, S. Mulligan, G. Bryant, B. Carpten, J. Gertz, M. Rajkumar, S. V. Lacy, M. Dispenzieri, A. Kyle, R. Greipp, P. Bergsagel, P. L. Fonseca, R.
Cancer Res 2007 Apr 1;67(7):2982-9   /  Apr 1, 2007

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts

Chesi, M. Nardini, E. Lim, R. S. Smith, K. D. Kuehl, W. M. Bergsagel, P. L.
Blood 1998 Nov 1;92(9):3025-34   /  Nov 1, 1998

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Chesi, M. Nardini, E. Brents, L. A. Schrock, E. Ried, T. Kuehl, W. M. Bergsagel, P. L.
Nat Genet 1997 Jul;16(3):260-4   /  Jul 1, 1997

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Chesi, M. Brents, L. A. Ely, S. A. Bais, C. Robbiani, D. F. Mesri, E. A. Kuehl, W. M. Bergsagel, P. L.
Blood 2001 Feb 1;97(3):729-36   /  Feb 1, 2001

Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma

Chesi, M. Bergsagel, P. L. Shonukan, O. O. Martelli, M. L. Brents, L. A. Chen, T. Schrock, E. Ried, T. Kuehl, W. M.
Blood 1998 Jun 15;91(12):4457-63   /  Jun 15, 1998

Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines

Chesi, M. Bergsagel, P. L. Brents, L. A. Smith, C. M. Gerhard, D. S. Kuehl, W. M.
Blood 1996 Jul 15;88(2):674-81   /  Jul 15, 1996

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

Carrasco, D. R. Tonon, G. Huang, Y. Zhang, Y. Sinha, R. Feng, B. Stewart, J. P. Zhan, F. Khatry, D. Protopopova, M. Protopopov, A. Sukhdeo, K. Hanamura, I. Stephens, O. Barlogie, B. Anderson, K. C. Chin, L. Shaughnessy, J. D., Jr. Brenna
Cancer Cell 2006 Apr;9(4):313-25   /  Apr 1, 2006

The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis

Carrasco, D. R. Sukhdeo, K. Protopopova, M. Sinha, R. Enos, M. Carrasco, D. E. Zheng, M. Mani, M. Henderson, J. Pinkus, G. S. Munshi, N. Horner, J. Ivanova, E. V. Protopopov, A. Anderson, K. C. Tonon, G. Depinho, R. A.
Cancer Cell 2007 Apr;11(4):349-60   /  Apr 1, 2007

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

Bergsagel, P. L. Kuehl, W. M. Zhan, F. Sawyer, J. Barlogie, B. Shaughnessy, J., Jr.
Blood 2005 Jul 1;106(1):296-303   /  Jul 1, 2005

Chromosome translocations in multiple myeloma

Bergsagel, P. L. Kuehl, W. M.
Oncogene 2001 Sep 10;20(40):5611-22   /  Sep 10, 2001

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

Barlogie, B. Tricot, G. Rasmussen, E. Anaissie, E. van Rhee, F. Zangari, M. Fassas, A. Hollmig, K. Pineda-Roman, M. Shaughnessy, J. Epstein, J. Crowley, J.
Blood Apr 1;107(7):2633-8   /  Apr 1, 2006

Multiple myeloma: evolving genetic events and host interactions

Kuehl, W. M., Bergsagel, P. L.
Nat Rev Cancer 2002 Mar;2(3):175-87   /  Mar 1, 2002